Basel Medical Group (BMGL) Fair Value & Analysis
Healthcare · US · Market cap $10.7M
Fair value as of: Jun 24, 2026
Analysis
Basel Medical Group (BMGL) currently trades at $6.93, while our model-based Fair Value estimate is $0.9000 — implying the stock looks roughly 87.0% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Basel Medical Group Ltd provides healthcare services in Singapore. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments. It also provides health screening services, mental health, woman's health, and general practice services. In addition, its services include consultation, medical diagnosis, and medical and surgical treatments. The company was incorporated in 2023 and is headquartered in Singapore.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Basel Medical Group (BMGL) undervalued?
What is the fair value of BMGL?
What is the quality score of BMGL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.